Design Therapeutics Inc
$ 10.97
4.18%
12 Jun - close price
- Market Cap 657,672,000 USD
- Current Price $ 10.97
- High / Low $ 11.02 / 10.51
- Stock P/E N/A
- Book Value 3.49
- EPS -1.20
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.31 %
- 52 Week High 17.25
- 52 Week Low 3.33
About
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad, California.
Analyst Target Price
$21.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-28 | 2026-03-09 | 2025-11-05 | 2025-08-07 | 2025-05-07 | 2025-03-10 | 2024-11-07 | 2024-08-05 | 2024-05-08 | 2024-03-19 | 2023-11-13 | 2023-08-14 |
| Reported EPS | -0.29 | -0.27 | -0.3 | -0.34 | -0.31 | -0.24 | -0.23 | -0.21 | -0.2 | -0.21 | -0.28 | -0.36 |
| Estimated EPS | -0.35 | -0.33 | -0.3367 | -0.2967 | -0.28 | -0.2667 | -0.24 | -0.23 | -0.26 | -0.31 | -0.41 | -0.4 |
| Surprise | 0.06 | 0.06 | 0.0367 | -0.0433 | -0.03 | 0.0267 | 0.01 | 0.02 | 0.06 | 0.1 | 0.13 | 0.04 |
| Surprise Percentage | 17.1429% | 18.1818% | 10.8999% | -14.5939% | -10.7143% | 10.0112% | 4.1667% | 8.6957% | 23.0769% | 32.2581% | 31.7073% | 10% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.36 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DSGN
2026-06-12 03:09:58
Design Therapeutics (NASDAQ: DSGN) has released the results of its 2026 Annual Meeting of Stockholders. Shareholders re-elected Simeon George, M.D. as a Class II director and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The report details the specific vote counts for each proposal, including votes for, votes withheld, and broker non-votes.
2026-06-11 20:40:35
Design Therapeutics (DSGN) director Rodney W. Lappe was granted 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months following June 9, 2026, or fully by the company's next annual stockholder meeting. This transaction was reported as compensation in a Form 4 SEC filing.
2026-06-11 20:40:35
Design Therapeutics (DSGN) director Justin D. Gover has been granted stock options for 30,000 shares of common stock. These options have an exercise price of $10.55 per share and an expiration date of June 8, 2036. The shares will vest in equal monthly installments over 12 months starting June 9, 2026, or fully by the company's next annual meeting, whichever comes first.
2026-06-11 20:40:35
Design Therapeutics, Inc. director John P. Schmid was granted 30,000 stock options with an exercise price of $10.55 per share, expiring in 2036. These options will vest in equal monthly installments over 12 months starting June 9, 2026, or fully vest by the company's next annual meeting. Following this transaction, Schmid directly holds options for 30,000 shares of Design Therapeutics (DSGN).
2026-06-11 20:40:35
Design Therapeutics (DSGN) director Heather A. Berger was granted 30,000 stock options with an exercise price of $10.55 per share. These options will vest in equal monthly installments over 12 months following June 9, 2026, or fully vest by the company's next annual meeting of stockholders, aligning with her board service. The transaction is reported as neutral in impact and sentiment.
2026-06-09 21:09:03
Point72-affiliated entities, including Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen, have reported a passive 5.1% stake in Design Therapeutics (DSGN). This holding amounts to 3,197,764 shares of common stock as of June 8, 2026, with shared voting and dispositive power. The disclosure was made via a Schedule 13G filing, indicating an investment purpose rather than an intent to control the company.
